Table 1.
Patients and treatment characteristics
| Characteristic | Value |
|---|---|
| Age (yr) | 68 (50–78) |
| Surgery type | |
| Laparoscopic | 79 (47.0) |
| Robotic | 53 (31.6) |
| Retropubic | 33 (19.6) |
| Transperineal | 3 (1.8) |
| Pathologic T stage | |
| 1–2 | 54 (32.2) |
| 3a | 65 (38.7) |
| 3b–4 | 46 (27.3) |
| Unknown | 3 (1.8) |
| Pathologic N stage | |
| 0 | 159 (94.6) |
| 1 | 9 (5.4) |
| Postoperative Gleason score | |
| ≤6 | 10 (6.0) |
| 7 | 72 (42.8) |
| ≥8 | 82 (48.8) |
| Unknown | 4 (2.4) |
| Resection margin | |
| Negative | 89 (53.0) |
| Positive | 79 (47.0) |
| Lymphovascular invasion | |
| No | 143 (85.1) |
| Yes | 25 (14.9) |
| Perineural invasion | |
| No | 39 (23.2) |
| Yes | 129 (76.8) |
| PSA level (ng/mL) | |
| Initial | 14.930 (2.140-177.000) |
| At PORT (ng/mL) | 0.275 (0.001-97.184) |
| Treatment setting | |
| Adjuvant | 48 (28.6) |
| Salvage | 120 (71.4) |
| RT dose | 67.2 (60.0–72.6) |
| RT dose, EQD2/2 | 69.3 (60.0–76.2) |
| RT volume | |
| Surgical bed only | 46 (27.4) |
| Whole pelvis | 122 (72.6) |
| RT method | |
| IMRT | 121 (72.0) |
| 3D-CRT | 24 (14.3) |
| Mixed | 23 (13.7) |
| NA-ADT | |
| No | 113 (67.3) |
| Yes | 55 (32.7) |
| CA-ADT | |
| No or unknown | 41 (24.4) |
| Yes | 127 (75.6) |
Values are presented as median (range) or number (%).
PSA, prostate-specific antigen; PORT, postoperative radiotherapy; RT, radiotherapy; EQD2/2, equivalent dose in 2 Gy fractions at α/β ratio of 2.0; IMRT, intensity-modulated radiotherapy; 3D-CRT, three-dimensional conformal radiotherapy; NA-ADT, neoadjuvant androgen deprivation therapy before PORT; CA-ADT, concurrent or adjuvant androgen deprivation therapy with PORT.